• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Role of Vitamins in Cardiovascular Health: Know Your Facts - Part 1
Curr Vasc Pharmacol. 2023 Sep 12. doi: 10.2174/1570161121666230912155548. Online ahead of print.ABSTRACTCardiovascular (CV) disease (CVD) is a major cause of morbidity and mortality world-wide, thus it is important to adopt preventive interventions. Observational data demonstrating CV benefits of vitamin supplements, advanced by self-proclaimed experts have resulted in ~50% of Americans reporting the use of multivitamins for health promotion; this practice has led to a multi-billion-dollar business of the multivitamin-industry. However, the data on the extensive use of multivitamins show no consistent benefit for CVD preve...
Source: Current Vascular Pharmacology - September 13, 2023 Category: Drugs & Pharmacology Authors: Antonis A Manolis Theodora A Manolis Helen Melita Antonis S Manolis Source Type: research

Lipoprotein(a) and Cardiovascular Diseases 　- Revisited.
Lipoprotein(a) and Cardiovascular Diseases　- Revisited. Circ J. 2020 Apr 24;: Authors: Jang AY, Han SH, Sohn IS, Oh PC, Koh KK Abstract Two decades ago, it was recognized that lipoprotein(a) (Lp(a)) concentrations were elevated in patients with cardiovascular disease (CVD). However, the importance of Lp(a) was not strongly established due to a lack of both Lp(a)-lowering therapy and evidence that reducing Lp(a) levels improves CVD risk. Recent advances in clinical and genetic research have revealed the crucial role of Lp(a) in the pathogenesis of CVD. Mendelian randomization studies have shown that ...
Source: Circulation Journal - April 23, 2020 Category: Cardiology Authors: Jang AY, Han SH, Sohn IS, Oh PC, Koh KK Tags: Circ J Source Type: research

Lipid-lowering agents in older individuals: A systematic Review and Meta-analysis of Randomized Clinical Trials.
CONCLUSION: High-certainty evidence supports statin use for secondary prevention in older individuals. Evidence for primary prevention is less certain. Data in older individuals with diabetes are limited; however, no empirical evidence has shown a significant difference based on diabetes status. PMID: 30903687 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - March 22, 2019 Category: Endocrinology Authors: Ponce OJ, Larrea-Mantilla L, Hemmingsen B, Serrano V, Rodriguez Gutierrez R, Spencer-Bonilla G, Alvarez-Villalobos N, Benkhadra K, Haddad A, Gionfriddo MR, Prokop LJ, Brito JP, Murad MH Tags: J Clin Endocrinol Metab Source Type: research

Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs Original Articles
Conclusions— In HPS2-THRIVE, the addition of extended-release niacin–laropiprant to statin-based therapy reduced quality of life–adjusted survival and increased hospital costs. Clinical Trial Registration— URL: http://clinicaltrials.gov. Unique identifier: NCT00461630.
Source: Circulation: Cardiovascular Quality and Outcomes - July 18, 2016 Category: Cardiology Authors: Kent, S., Haynes, R., Hopewell, J. C., Parish, S., Gray, A., Landray, M. J., Collins, R., Armitage, J., Mihaylova, B., on behalf of the HPS2-THRIVE Collaborative Group Tags: Cardiovascular Disease, Treatment, Cost-Effectiveness, Quality and Outcomes, Vascular Disease Original Articles Source Type: research